RSLS vs. NUWE, KALA, ACST, ECOR, IRIX, ABT, ISRG, SYK, BSX, and MDT
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include Nuwellis (NUWE), KALA BIO (KALA), Acasti Pharma (ACST), electroCore (ECOR), IRIDEX (IRIX), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), and Medtronic (MDT).
ReShape Lifesciences (NASDAQ:RSLS) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
ReShape Lifesciences received 379 more outperform votes than Nuwellis when rated by MarketBeat users. Likewise, 66.22% of users gave ReShape Lifesciences an outperform vote while only 50.00% of users gave Nuwellis an outperform vote.
In the previous week, ReShape Lifesciences and ReShape Lifesciences both had 3 articles in the media. ReShape Lifesciences' average media sentiment score of 0.99 beat Nuwellis' score of 0.72 indicating that ReShape Lifesciences is being referred to more favorably in the media.
22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 0.1% of ReShape Lifesciences shares are owned by insiders. Comparatively, 2.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ReShape Lifesciences has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
ReShape Lifesciences has a net margin of -130.99% compared to Nuwellis' net margin of -202.97%. ReShape Lifesciences' return on equity of -207.78% beat Nuwellis' return on equity.
ReShape Lifesciences has higher earnings, but lower revenue than Nuwellis.
Summary
ReShape Lifesciences beats Nuwellis on 9 of the 12 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ReShape Lifesciences Competitors List
Related Companies and Tools
